-

Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has successfully met the primary endpoints in its Phase 1 clinical trial. The trial demonstrated pharmacokinetic equivalence to the US-licensed and EU-authorized reference product, ORENCIA®.

KSHB002, a 125 mg/mL pre-filled syringe injection, was evaluated in a randomized, open-label study involving 300 healthy male and female adults. The study was designed with three parallel arms and assessed the pharmacokinetics, safety, and immunogenicity of KSHB002 compared to the reference product. All participants received a single subcutaneous dose.

The results demonstrated that both primary endpoints, maximum serum concentration (Cmax) and area under the concentration-time curve from time zero to infinity (AUC₀–∞), were within the 80-125% bioequivalence range, confirming pharmacokinetic equivalence. Furthermore, the safety and immunogenicity profiles of KSHB002 were comparable to those of ORENCIA®.

Kashiv Biosciences is developing the proposed abatacept biosimilar as both subcutaneous and intravenous formulations.

“We are thrilled with the results of our Phase 1 study and are excited to move forward with our global Phase 3 efficacy and safety trial. This represents a pivotal step in advancing the evaluation of KSHB002 for patients with rheumatoid arthritis,” stated Dr. Sandeep Athalye, CEO of Kashiv Biosciences.

About Kashiv Biosciences:

Kashiv Biosciences, LLC is a vertically integrated biopharmaceutical company with a diverse portfolio of commercial and advanced clinical-stage assets. Operating in the United States and India, Kashiv Biosciences leverages robust infrastructure and highly skilled teams to deliver global R&D, clinical, manufacturing, regulatory, and IP capabilities. Our mission is to advance patient care and improve access to affordable essential medicines.

Contacts

Dr. Paras Vasanani
paras.vasanani@kashivbio.com
www.kashivbiosciences.com

Industry:

Kashiv Biosciences, LLC

Release Versions
English

Contacts

Dr. Paras Vasanani
paras.vasanani@kashivbio.com
www.kashivbiosciences.com

More News From Kashiv Biosciences, LLC

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a fully-integrated biopharmaceutical company, announced that they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA), for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The submissions are intended to seek approval in the United States and the European Economic Area, respectively....

Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC today announced the commercial launch of PEXEGRA®, a biosimilar referencing Neulasta®, and FILRA®, a biosimilar referencing Neupogen®, in the Canadian market. Both biosimilars will be marketed in Canada through an exclusive agreement with JAMP Pharma Corporation. PEXEGRA® (6 mg/0.6 mL pre-filled syringe) and FILRA® (300 mcg/0.5 mL and 480 mcg/0.8 mL pre-filled syringe) are used to treat neutropenia, low neutrophils which are a type of w...

Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into a licensing and supply agreement with CRISTÁLIA, one of the leading pharmaceutical companies in Brazil, for the commercialization of ADL-018 / bOmalizumab, a proposed biosimilar to Xolair®, in Latin America (LATAM). In 2024, IQVIA recorded approximately $5.0 billion in global sales, with approximately $140 million contributed by the LATAM region. Under the terms of the...
Back to Newsroom